Summary:
Scientists from the Manchester Collaborative Center for Inflammation Research found out why the drug rituximab is so effective at killing cancerous B cells. The researchers used high powered microscopes to record the process of rituximab binding to a diseased cell. They found that rituximab usually formed a cap by drawing a number of proteins to one side of the cell. When a natural killer cell latched onto a cell that had a cap formed from rituximab, it had an 80% success rate on killing the cell. When there was no cap, the diseased cell was only killed 40% of the time. Professor Daniel Davis will continue to use the same technology to investigate more about immunology at the Manchester Collaborative Center for Inflammation Research.
Themes of Science:
Science is collaborative - The research was carried out in collaboration with MedImmune, a research and development arm of AstraZeneca.
Science is based on evidence - The researchers used evidence from high powered video recordings.
Importance of repeatability - Professor Davis is going to continue to use the same technology to study immunology more in depth.
Katherine Gao Hour 1 Gabel
No comments:
Post a Comment